Roles of Gut Microbiota and Sera Metabolomics in Amelioration of Diabetes and Metabolic Syndrome by Bariatric Surgery

腸道微生物群和血清代謝體於減肥手術改善糖尿病與代謝綜合症的角色

Diabetes and the related metabolic syndrome have been causing important public health problems worldwide. Among the different ways in management of diabetes, Bariatric surgery (BS) has emerged and reckoned as a very efficient treatment approach. Current understandings of the underlying ameliorative mechanisms in BS treatment were closely associated with alterations in multiple important parameters related to laboratory biochemical test results, reduction in energy absorption, release of gastrointestinal hormones, reduction in adipose tissues and body weight, and recently, gut microbiota structure and sera metabolites. In this review, we first make a background introduction on diabetes and BS. This is followed by presenting the recent developments in gut microbiota and sera metabolomics in relation to BS effects. While BS operations are still under intensive development, roles of gut microbiota and its related sera metabolomics are shown to significantly affect efficacy of amelioration of diabetes.

糖尿病和相關的代謝綜合症已在世界各地造成重要的公共衛生問題。針對糖尿病的不同治療方法中，減肥手術（BS）已經發展成為一種公認非常有效的治療方法。對BS治療中潛在的改善機制，目前了解與多個重要參數的變化密切相關。這些參數與實驗室生化測試結果、能量吸收減少、胃腸激素釋放、脂肪組織和體重減少，以及最近研究發現的腸道菌群結構和血清代謝組有關。本文獻回顧首先對糖尿病和BS作了背景介紹，接下來介紹與BS效應相關的腸道微生物群和血清代謝組學的最新進展。雖然BS手術仍在加強開發中，但腸道菌群及其相關的血清代謝組的作用對改善糖尿病的功效顯示出顯著的影響。